In this 3-part series, Hematology Advisor spoke with experts about the revisions to the ASH clinical practice guidelines for venous thromboembolism.
Researchers conducted a systematic literature review to characterize the complications experienced by patients with upper extremity deep vein thrombosis.
Changes in health-related quality of life in patients with persistent/chronic immune thrombocytopenia were evaluated using 4 different tools.
No differences were observed in patency rates or incidence of post-thrombotic syndrome in patients treated with rivaroxaban or a vitamin K antagonist.
Compared with warfarin, rivaroxaban was found to reduce the risk of overall, gastrointestinal, and intracranial bleeding.
Patients With Splanchnic Vein Thrombosis May Have Increased Risk of Bleeding and Arterial Cardiovascular Events
Researchers analyzed 1915 patients with splanchnic vein thrombosis for risk of bleeding and arterial cardiovascular events.
Researchers performed a retrospective review of 1279 patients treated with a standardized, weight-adjusted tinzaparin regimen.
Direct-Acting Oral Anticoagulants May Be Efficacious in Treating Cancer-Associated Venous Thrombosis
Researchers evaluated 12 studies including 4720 patients for recurrent VTE risk and major bleeding.
Prophylactic rituximab may decrease relapse in immune thrombotic thrombocytopenic purpura by maintaining detectable levels of ADAMTS13 activity.
Patients with pregnancy-onset ITP were more likely to deliver babies with neonatal thrombocytopenia compared with patients diagnosed before pregnancy.
Patients with VTE with moderate to severe thrombocytopenia at baseline were associated with increased risk for major bleeding events and all-cause mortality.
Forty-three percent of patients on fostamatinib and 14% on placebo achieved overall responses (defined as ≥1 platelet count ≥50,000/μL within the first 12 weeks on treatment).
A number of risk factors were associated with chronic thromboembolic pulmonary hypertension, including, age >70 years, female gender, and pulmonary embolism at first venous thromboembolism.
Perioperative red blood cell transfusion linked to increased adjusted odds of venous thromboembolism, deep vein thrombosis, and pulmonary embolism.
At the end of 6 months, the rate of VTE recurrence was 4% among rivaroxaban patients vs 11% in the dalteparin arm (hazard ratio [HR] 0.43, 95% CI: 0.19 to 0.99).